Logo of National Eczema Association mobile menu icon
Icon link to National Eczema's Instagram feed. Icon link to National Eczema's YouTube channel. Icon link to National Eczema's Facebook page. Icon link to National Eczema's Twitter feed. Icon link to National Eczema's inspire.com page. Search Icon to search the site

Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

Clinical Trial Details for 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Bausch Health Americas, Inc.
NCT ID: NCT00568997
Last Updated: November 21, 2019

The Study at a Glance

  • Status: Recruiting
  • Phase:
  • Gender: All
  • Age: 2 Years - 17 Years
  • Condition: Atopic Dermatitis
  • Study Type: Observational
  • Intervention:
  • Lead Sponsor: Bausch Health Americas, Inc.
  • Location: Not Provided

Official Title

A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)


This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.


Ages Eligible for Study

2 Years to 17 Years

Sexes Eligible for Study


Accepts Healthy Volunteers


Study Population

Children (ages 2-17 years)


Inclusion Criteria:

– males and females

– greater than or equal to 2 years and less than or equal to 17 years at enrollment

– diagnosis of atopic dermatitis (confirmed by treating physician)

– applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks

Exclusion Criteria:

– past or present history of systemic malignancy, skin malignancy, or
lymphoproliferative disease

– past or present use of oral immunosuppressive therapy

Additional Information, Locations & Contacts

Sponsors & Collaborators

Bausch Health Americas, Inc.

Clinical Research Computing Unit (University of Pennsylvania)


Not Provided

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568997




Philadelphia, Pennsylvania 19104

United States